Previous Close | 6.77 |
Open | 6.83 |
Bid | 6.76 x N/A |
Ask | 6.87 x N/A |
Day's Range | 6.83 - 6.83 |
52 Week Range | 6.33 - 8.67 |
Volume | |
Avg. Volume | 0 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of
NEW YORK & DÜSSELDORF, Germany, January 17, 2023--Asahi Kasei, a diversified Japanese multinational company, has developed a new technology for recycling carbon fiber plastic compounds together with the National Institute of Technology, Kitakyushu College and Tokyo University of Science.
NEW YORK & TOKYO, January 05, 2023--Asahi Kasei, a diversified Japanese multinational company, is showcasing how mobility and living will seamlessly connect the virtual space to the physical space at CES 2023, including their new concept vehicle, AKXY2. The organization will also highlight innovations that exemplify how sustainability can be applied to technology to benefit the environment while increasing enjoyment and satisfaction for society.